Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

• BREAST CANCER COHORT:
• Women newly diagnosed (stage I-III) breast cancer
• Are overweight or obese with the following criteria (determined by study team at eligibility screening): body mass index (BMI) > 25 kg/m\^2 (calculated using height and weight; an upper limit BMI will not be set; we will rely on obtaining physicians? clearance to assess full eligibility) or body fat > 30% (estimated by bioelectrical impedance), and waist circumference > 35 in
• Have undergone a lumpectomy or mastectomy
• Have completed cancer-related treatment within the past 3 years
• Speak English or Spanish
• Are in breast cancer remission with no detectable disease present
• Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity)
• Free from history of chronic disease including uncontrolled diabetes (fasting blood glucose > 125 mg/dL), hypertension (blood pressure > 130/90 mmHg) or thyroid disease (\< 0.4 or > 4.0 mIU/L); this will be determined by review of medical records and/or physician clearance
• Have not experienced a weight reduction >= 10% within past 6 months
• Currently participate in less than 60 minutes of structured exercise/week
• No planned reconstructive surgery with flap repair during trial and follow-up period
• May use adjuvant endocrine therapy if use will be continued for duration of study intervention
• Do not smoke (no smoking during previous 12 months)
• Willing to travel to the exercise facility at University of Southern California (USC)
• PROSTATE CANCER COHORT:
• Men > 18 diagnosed with prostate cancer for which antiandrogen therapy (ADT) (castration therapy) is being prescribed for at least 16 weeks; castration may be achieved surgically or using gonadotrophin releasing hormone (LHRH) agonists (i.e. leuprolide, goserelin, etc.) or LHRH antagonists (i.e. degarelix)
• Additional ADT agents may be concurrently administered (abiraterone, bicalutamide, enzalutamide, etc.)
• Men must be obese (BMI > 25) and sedentary (\< 60 minutes of structured exercise per week)

Exclusion Criteria:

• Patients with metastatic disease (BREAST ONLY)
• Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapy
• Patients with a history of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise must be evaluated by their physician to assess if they are suitable to proceed on study
• Are planning reconstructive surgery with flap repair during trial and follow-up period
• Are unable to travel to the exercise facility at USC